Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 1977-1985

  Chang, Chin Hao ^a   Hsiao, Chin Fu ^b   Yeh, Yu Min ^c,d   Chang, Gee Chen ^e,f   Tsai, Ying Huang ^g   Chen, Yuh Min ^h,i   Huang, Ming Shyan ^j   Chen, Hui Ling ^b   Li, Yao Jen ^k,l   Yang, Pan Chyr ^a   Chen, Chien Jen ^k,l   Hsiung, Chao A ^b   Su, Wu Chou ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e Division of Chest Medicine   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^j KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k GENOMICS RESEARCH CENTER   (Taiwan)

^l NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

Interleukin 6; lung cancer; prognostic factor; survival

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6;

AGE DISTRIBUTION; ANAMNESIS; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENDER; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SMOKING; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874109197     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27892     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Department of Health, Executive Yuan, Taiwan, Republic of China. Cancer Registry Annual Report. Taipei, Taiwan: Executive Yuan, Taiwan, Republic of China; 2006.
3. Department of Health, Executive Yuan, Taiwan, Republic of China. Health and vital statistics, vol II. Vital Statistics. Taipei, Taiwan: Executive Yuan, Taiwan, Republic of China; 2006.
4. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010; 28: 4417-24.
5. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-7.
6. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
7. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and combination with erlotinib. J Clin Oncol 2005; 23: 5900-9.
9. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26: 1472-8.
10. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356: 11-20.
11. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-8.
12. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 1878-85.
13. Hanash SM, Pitteri SJ, Face VM,. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452: 571-9.
14. George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11: 1815-20.
15. Scheller J, Rose-John S,. Interleukin-6 and its receptor: form bench to bedside. Med Microbiol Immunol 2006; 195: 173-83.
16. Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-65.
17. Ljungberg B, Grankvist K, Rasmuson T,. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997; 33: 1794-8.
18. Fayad L, Cabanillas F, Talpaz M, et al. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 1998; 30: 563-71.
19. Liao WC, Lin JT, Wu CY, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcimoma. Clin Cancer Res 2008; 14: 428-34.
20. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
21. De Vita F, Romano C, Orditura M, et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21: 45-52.
22. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103: 642-6.
23. Martín F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11: 80-6.
24. Songür N, Kuru B, Kalkan F, et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90: 196-200.
25. De Vita F, Orditura M, Auriemma A, et al. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5: 649-52.
26. Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71: 1095-8.
27. Wang TH, Chan YH, Chen CW, et al. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 2006; 25: 4857-66.
28. Poth KJ, Guminski AD, Thomas GP, et al. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high Interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther 2010; 9: 2430-9.
29. Chang CH, Hsiao CF, Chang GC, et al. Interactive effect of cigarette smoking with hOGG1 polymorphisms on the risk of lung cancer: a case-control study in Taiwan. Am J Epidemiol 2009; 170: 695-702.
30. Patrick Therasse P, Arbuck SG, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
31. Lu TH, Lee MC, Chou MC,. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol 2000; 29: 336-43.
32. Utsumi K, Takai Y, Tada T, et al. Enhanced production of IL-6 in tumor-beraing mice and determination of cells responsible for its augmented production. J Immunol 1990; 145: 397-403.
33. Yamaji H, Iizasa T, Koh E, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 2004; 53: 786-92.
34. Schafer ZT, Brugge JS,. IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117: 3660-3.
35. Sunyer J, Forastiere F, Pekkanen J, et al. Interaction between smoking and the interleukin-6 gene affects systemic levels of inflammatory biomarkers. Nicotine Tob Res 2009; 11: 1347-53.
36. Ershler WB, Sun WH, Binkley N, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12: 225-30.
37. O'Connor MF, Motivala SJ, Valladares EM, et al. Sex differences in monocyte expression of IL-6: role of autonomic mechanisms. Am J Physiol Regul Integr Comp Physiol 2007; 293: R145-51.
38. Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61: 8851-8.
39. Wojciechowska-Lacka A, Adamiak E, Stryczynska G, et al. Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report. Yale J Biol Med 1997; 70: 139-48.
40. Su C, Zhou C, Zhou S, et al. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol 2011; 28: 1453-7.
41. Gilbert L A, Hemann MT,. DNA damage-mediated induction of a chemoresistant niche. Cell 2010; 143: 355-66.
42. Butterfield LH, Potter DM, Kirkwood JM,. Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med 2011; 9: 173.
43. Potter DM, Butterfield LH, Divito SJ, et al. Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J Immunol Methods 2012; 376: 108-112.